Table 3. ADAMTS13 activity and... | American Society of Hematology

Table 3.

ADAMTS13 activity and anti-ADAMTS13 as predictors of outcome during the acute phase of acquired thrombotic thrombocytopenic purpura (TTP).

			Outcomes (% of patients)
Factors compared	Authors	Study design	Remission	Death
*Severe ADAMTS13 deficiency identifies patients with plasma levels of less than 10% of normal; nonsevere deficiency, all levels above
†Denotes information not available or not retrievable from the manuscript.
Severe vs nonsevere ADAMTS13 deficiency*	Vesely et al¹⁸	Prospective	84 vs 55	16 vs 45
	Zheng et al²⁰	Prospective	82 vs 49	18 vs 51
	Mori et al¹⁷	Retrospective	85 vs 20	15 vs 80
	Coppo et al¹⁹	Retrospective	NA†	13 vs 0
	Raife et al³⁵	Retrospective	NA†	8 vs 18
Present vs absent anti-ADAMTS13	Zheng et al²⁰	Prospective	75 vs 100	25 vs 0
	Coppo et al³⁷	Retrospective	81 vs 100	19 vs 0
	Mori et al¹⁷	Retrospective	67 vs 100	33 vs 0
	Bohm et al³⁶	Retrospective	84 vs 100	16 vs 0

			Outcomes (% of patients)
Factors compared	Authors	Study design	Remission	Death
*Severe ADAMTS13 deficiency identifies patients with plasma levels of less than 10% of normal; nonsevere deficiency, all levels above
†Denotes information not available or not retrievable from the manuscript.
Severe vs nonsevere ADAMTS13 deficiency*	Vesely et al¹⁸	Prospective	84 vs 55	16 vs 45
	Zheng et al²⁰	Prospective	82 vs 49	18 vs 51
	Mori et al¹⁷	Retrospective	85 vs 20	15 vs 80
	Coppo et al¹⁹	Retrospective	NA†	13 vs 0
	Raife et al³⁵	Retrospective	NA†	8 vs 18
Present vs absent anti-ADAMTS13	Zheng et al²⁰	Prospective	75 vs 100	25 vs 0
	Coppo et al³⁷	Retrospective	81 vs 100	19 vs 0
	Mori et al¹⁷	Retrospective	67 vs 100	33 vs 0
	Bohm et al³⁶	Retrospective	84 vs 100	16 vs 0